Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ejection Fraction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,222 result(s) found for: Ejection Fraction. Displaying page 1 of 62.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-002336-17 Sponsor Protocol Number: REDUCe_2017-05-22 Start Date*: 2017-08-06
    Sponsor Name:Department of Clinical Sciences, Danderyd Hospital, Karolinska Intitutet
    Full Title: Randomized Evaluation of Decreased Usage of betablocCkErs after myocardial infarction in the SWEDEHEART registry REDUCe SWEDEHEART
    Medical condition: Long-term treatment with beta-blockers in patients with myocardial infarction and preserved ejection fraction.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) EE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003461-17 Sponsor Protocol Number: 71272 Start Date*: 2020-01-07
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Pathophysiological relevance of IRON deficiency and related mitochondrial dysfunction in Heart Failure with Preserved Ejection Fraction (IRON-HFpEF)
    Medical condition: Heart failure with preserved ejection fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002091-41 Sponsor Protocol Number: 03618 Start Date*: 2014-10-09
    Sponsor Name:Academisch medisch centrum
    Full Title: Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system
    Medical condition: To study the effect of losartan in adult patients with Tetralogy of Fallot and right ventricular dysfunction, defined as right ventricular ejection fraction <50%. Without severe valvular lesions.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001488-21 Sponsor Protocol Number: EST:15/17 Start Date*: 2018-11-06
    Sponsor Name:Sergio Aleman
    Full Title: EFFECT OF VITAMIN D SUPPLEMENTATION ON THE VENTRICULAR DEFORMATION RATE (STRAIN RATE) IN PATIENTS WITH HEART FAILURE WITH PRESERVED OR MODERATELY REDUCED EYECTION FRACTION
    Medical condition: Heart failure with preserved or moderately reduced eyection fraction
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004656-30 Sponsor Protocol Number: ICOR-2016-05 Start Date*: 2018-10-19
    Sponsor Name:Instituto de Investigación en Ciencias de la Salud Germans Trias i Pujol (IGTP)
    Full Title: EVOlocumab in stable Heart Failure with reduced ejection fraction of ischemic etiology: EVO-HF Pilot
    Medical condition: stable coronary artery disease and stable heart failure with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-000671-25 Sponsor Protocol Number: 1242-001 Start Date*: 2016-09-30
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi- Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in S...
    Medical condition: Treatment of chronic heart failure with reduced ejection fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) DK (Completed) NL (Completed) FI (Completed) PL (Completed) BE (Completed) GR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-003653-15 Sponsor Protocol Number: AC-055G202 Start Date*: 2017-09-12
    Sponsor Name:ACTELION Pharmaceuticals Ltd
    Full Title: A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascu...
    Medical condition: Heart failure with preserved ejection fraction and pulmonary vascular disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) AT (Completed) SE (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-004072-59 Sponsor Protocol Number: 1245-0167 Start Date*: 2018-04-03
    Sponsor Name:Boehringer-Ingelheim España, S.A.
    Full Title: A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In pa...
    Medical condition: Chronic Heart Failure with preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) PT (Completed) PL (Completed) SE (Completed) NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001341-27 Sponsor Protocol Number: Empire-2017 Start Date*: 2017-05-29
    Sponsor Name:Morten Schou
    Full Title: Empagliflozin in heart failure patients with reduced ejection fraction: A randomized clinical trial (Empire HF)
    Medical condition: Heart failure with reduced ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-003055-60 Sponsor Protocol Number: RIO-40400 Start Date*: 2014-10-10
    Sponsor Name:Medical University of Vienna
    Full Title: Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction in a randomized, double blind, placebo controlled, ...
    Medical condition: Pulmonary hypertension and heart failure with preserved ejection fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005878-10 Sponsor Protocol Number: ISIS757456-CS5 Start Date*: 2021-05-06
    Sponsor Name:Ionis Pharmaceuticals
    Full Title: A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Phase 2 Study assessing the Safety, Tolerability and Efficacy of IONIS-AGT-LRX, an Antisense Inhibitor of Angiotensinogen Production, Ad...
    Medical condition: Chronic Heart Failure with Reduced Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-002653-31 Sponsor Protocol Number: VF20040171 Start Date*: 2004-11-25
    Sponsor Name:Odense University hospital
    Full Title: CAPHI. Profylactic effect of Ca2+ sensitizer versus phosphodiesterase inhibitor infusion at CAGB patients with preoperative low ejection fraction. A prospective randomised clinical trial.
    Medical condition: Perioperative use of Milrinon to CAGB patients has shown to reduce postoperative complications. Levosimendan improves cardiac performance without interfering with the calcium turnover and there by ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000802-46 Sponsor Protocol Number: D169CC00001 Start Date*: 2018-09-24
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failur...
    Medical condition: Heart Failure with Preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) PL (Completed) HU (Ongoing) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-003839-38 Sponsor Protocol Number: BAY1067197/15128 Start Date*: 2017-03-09
    Sponsor Name:Bayer AG
    Full Title: A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral parti...
    Medical condition: chronic heart failure with reduced ejection fraction (LVEF equal or below 35%)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) BE (Completed) GR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006611-68 Sponsor Protocol Number: shey01.2006 Start Date*: 2007-05-07
    Sponsor Name:academic hospital Maastricht
    Full Title: Valsartan on top of standard therapy as a novel therapeutic strategy to treat cardiac dysfunction in patients with infammatory cardiomyopathies
    Medical condition: patients suffering from heartfailure and inflammatory cardiomyopthies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002914-30 Sponsor Protocol Number: LCZ696-17 Start Date*: 2017-11-06
    Sponsor Name:FIMABIS
    Full Title: LCZ696 in heart failure patients with reduced ejection fraction and high comorbidity: effect on left ventricular remodeling and fibrosis assessed by novel heart failure biomarkers and cardiac magne...
    Medical condition: Chronic heart failure NYHA class II-IV with reduced ejection fraction (EF =< 40%) and elevated NT-proBNP ≥ 600 pg/mL, but 400 pg/mL if hospitalized for heart failure within 12 months
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003604-31 Sponsor Protocol Number: PREFER-HF Start Date*: 2017-02-09
    Sponsor Name:José Luis Morales Rull, Institut de Recerca Biomédica Lleida IRB Hospital Arnau de Vilanova Servicio de Medicina Interna
    Full Title: Effects of intravenous iron therapy with ferric carboxymaltose compared with oral iron therapy in heart failure with preserved ejection fraction and iron deficiency. ( PREFER-HF)
    Medical condition: Patients with heart failure with preserved ejection fraction ( HFpEF) and iron deficency anemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005053-37 Sponsor Protocol Number: IVOFER-HF Start Date*: 2019-02-08
    Sponsor Name:José Luis Morales Rull. Institut de Recerca Biomèdica de Lleida (IRBLleida)
    Full Title: Effect on the functional capacity of treatment with intravenous iron carboxymaltose or oral iron sucrosomial in patients with heart failure with depressed left ventricular ejection fraction and iro...
    Medical condition: Patients with heart failure with reduced ejection fraction ( HFrEF) and iron deficency.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003442-16 Sponsor Protocol Number: D169EC00002 Start Date*: 2019-04-17
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients wi...
    Medical condition: Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004452-11 Sponsor Protocol Number: EX9536-4665 Start Date*: 2021-02-04
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect of semaglutide 2.4 mg once weekly on function and symptoms in subjects with obesity-related heart failure with preserved ejection fraction
    Medical condition: Heart failure with preserved ejection fraction Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) NL (Completed) DE (Completed) DK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 04 13:41:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA